PARNATE

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Estonia, Ireland, New Zealand.

Active ingredients

The drug PARNATE contains one active pharmaceutical ingredient (API):

1	Tranylcypromine UNII 7ZAT6ES870 - TRANYLCYPROMINE SULFATE
	Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor for the treatment of symptoms of depressive illness especially where phobic symptoms are present or where treatment with other types of anti-depressants has failed.

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PARNATE Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AF04	Tranylcypromine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AF Monoamine oxidase inhibitors, non-selective
Discover more medicines within N06AF04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2444P
BR	Câmara de Regulação do Mercado de Medicamentos	510612110048403
CA	Health Products and Food Branch	01919598
EE	Ravimiamet	1799972, 1799994
IE	Health Products Regulatory Authority	39722
NZ	Medicines and Medical Devices Safety Authority	3412
US	FDA, National Drug Code	59212-447